MedTrace Logo

Gala Treatment for Chronic Bronchitis in Canada

NCT03385616 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-04

No results posted yet for this study

Summary

Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis in Canada.

Conditions

  • Chronic Bronchitis
  • COPD

Interventions

DEVICE

Gala Airway Treatment System

The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.

Sponsors & Collaborators

  • Gala Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • William Krimsky, MD · Gala Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-24
Primary Completion
2020-07-30
Completion
2021-02-28
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385616 on ClinicalTrials.gov